Pr ostate cancer (PCa) is the second leading cause of cancer death in men in the United States (1) . Conventional imaging techniques (e.g., CT) have played a relatively minor role in the management of organ-confined PCa, and novel imaging techniques including PET could play an important role in the detection of localized and locally recurrent PCa (2) . It is crucial to develop novel imaging probes and techniques for the primary diagnosis, follow-up, and monitoring of the recurrence of PCa. The clinical evaluation of certain PET probes, such as 18 F-FDG and radiolabeled acetate and choline, has highlighted the pivotal role that PET might play in the imaging and characterization of PCa patients. The discovery of novel PET molecular probes is expected to dramatically facilitate the diagnosis, prognosis, and stratification of PCa patients for effective therapeutic regimens (3) (4) (5) (6) (7) (8) .
Serum prostate-specific antigen testing has been a valuable tool in the detection, staging, and monitoring of PCa, but lack of specificity results in a high negative biopsy rate. Some biomarkers with high specificity for the disease in tissue have been identified, such as the gastrin-releasing peptide receptor (GRPR). Because it takes advantage of highly sensitive molecular imaging methods such as PET, GRPR-targeted PET imaging can be used for the detection, staging, and monitoring of PCa in a noninvasive and specific manner. GRPR is overexpressed in many human epithelial malignancies, including PCa (9,10), breast cancer (11) , and lung cancer (12) . GRPR-binding ligands represent potential diagnostic and therapeutic agents for the targeting of GRPR-positive tumors. Examples of such GRPR-binding ligands include mammalian gastrin-releasing peptide (GRP) and its amphibian homolog bombesin (BBN) (13) . These 2 peptides share homology in a C-terminal region, BBN (7) (8) (9) (10) (11) (12) (13) (14) , which is composed of the following 8 amino acid residues: Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH 2 . BBN (7) (8) (9) (10) (11) (12) (13) (14) has been extensively used for the development of molecular probes for the imaging of PCa (14) (15) (16) (17) (18) (19) . Moreover, a variety of BBN analogs, including both agonists and antagonists, has been radiolabeled with different radionuclides for GRPR-targeted PCa imaging and therapy (20) (21) (22) (23) (24) (25) (26) (27) (28) .
Among those GRPR-targeted peptides, RM1 (DOTA-CH 2 CO-G-4-aminobenzoyl-f-W-A-V-G-H-Sta-L-NH 2 , antagonist) (24) and AMBA (DOTA-CH 2 CO-G-4-aminobenzoyl-Q-W-A-V-G-H-L-M-NH 2 , agonist) (23) have been shown to be 2 promising GRPRtargeted peptide platforms for developing imaging and therapeutic agents for PCa. These 2 peptides have been radiolabeled with radiometals ( 111 In, 68 Ga, and 64 Cu) for SPECT and PET imaging of PCa (24) (25) (26) (27) . AMBA has also been radiolabeled with 177 Lu for radionuclide therapy of PCa (23, 28) . All of these radiocomplexes exhibit efficient tumor accumulation and favorable in vivo properties, which support their potential clinical application. More interestingly, 68 Ga-AMBA-based PET imaging has recently been found to be superior to metabolism-based imaging using 18 Fmethylcholine for scintigraphy of PCa (25) . These studies clearly suggest that the increased likelihood of successfully translating a BBN probe into the clinic can be achieved using AMBA and RM1 scaffolds.
However, 18 F-labeled RM1 and AMBA have not been explored, and currently there are no published data providing a head-to-head comparison of the performance of 18 F-labeled RM1 and AMBA analogs. 18 F is the most widely used radionuclide for clinical PET because of its ideal physical properties (;100% positron efficiency, low b1 energy [0.64 MeV], and physical half-life of 109.7 min). Moreover, 64 Cu has also gained extensive interest in the context of PET probe development and has been actively explored to label peptides for clinical imaging because of its many advantages including simple radiolabeling chemistry. Compared with 18 F, however, 64 Cu suffers from lower availability, longer half-life, and potential higher radiation dose (29) . In this study, we synthesized 1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid (NODAGA)-conjugated RM1 and AMBA (NODAGA-RM1, NODAGA-AMBA) peptides and then radiolabeled them via a simple 1-step chelation reaction ( 18 F-AlF [aluminum-fluoride] or 64 Cu) in aqueous phase (30) (31) (32) (33) to generate 18 F-AlF-NODAGA-RM1, 18 F-AlF-NODAGA-AMBA, 64 Cu-NODAGA-RM1, and 64 Cu-NODAGA-AMBA (Fig. 1) . We further evaluated these PET probes and compared them headto-head in PC3 tumor-bearing mice.
MATERIALS AND METHODS
All of the chemicals obtained commercially were of analytic grade and used without further purification. The PC3 human prostate carcinoma cell line was obtained from the American Type Culture Collection. Male nude mice were purchased from the Charles River Laboratory. 64 Cu was provided by the Department of Medical Physics, University of Wisconsin at Madison. No-carrier-added 18 F was obtained from an in-house PETtrace cyclotron (GE Healthcare). The Sep-Pak C18 cartridges were obtained from Waters. The syringe filters and polyethersulfone membranes (pore size, 0.22 mm; diameter, 13 mm) were obtained from Nalgene Nunc International. 125 I-[Tyr 4 ]BBN was purchased from PerkinElmer. 2,29-(7-(1-carboxy-4-((2,5-dioxopyrrolidin-1-yl)oxy)-4-oxobutyl)-1,4,7-triazonane-1,4-diyl)diacetic acid (NOTAGA-NHS) was purchased from CheMatech.
Reversed-phase high-performance liquid chromatography (HPLC) was performed using a Dionex 680 chromatography system with a UVD 170U absorbance detector and 105S single-channel model radiation detector (Carroll & Ramsey Associates). A Vydac protein and peptide column (218TP510; C18, 5 mm, 250 · 10 mm) was used for semipreparative HPLC at a flow rate of 4 mL/min. The mobile phase was maintained at a constant 95% for solvent A (0.1% trifluoroacetic acid [TFA] in water) and 5% for solvent B (0.1% TFA in acetonitrile [MeCN]) at 0-5 min and was subsequently changed to 35% for solvent A and 65% for solvent B at 35 min. A Vydac protein and peptide column (218TP510; C18, 5 mm, 250 · 4.6 mm) was used for the analytic HPLC at a flow rate of 1 mL/min. The mobile phase was changed from an initial 95% for solvent A and 5% for B (from 0 to 2 min) to 35% for solvent A and 65% for solvent B at 32 min. The recorded data were processed using Chromeleon software (version 6.50; Dionex). The ultraviolet absorbance was monitored at 218 nm, and the identification of the peptides was confirmed based on the ultraviolet spectrum using a PDA detector (Dionex).
Chemistry and Radiochemistry
Preparation of NODAGA-RM1 and NODAGA-AMBA. The G-4-aminobenzoyl-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH 2 (abbreviated as AMBA) and G-4-aminobenzoyl-D-Phe-Gln-Trp-Ala-Val-Gly-His-StaLeu-NH 2 (abbreviated as RM1) peptides (Fig. 1) were synthesized. Then the 2 peptides were conjugated with NODAGA-NHS to obtain NODAGA-AMBA and NODAGA-RM1, respectively. The detailed procedures are described in the supplemental file (supplemental materials are available at http://jnm.snmjournals.org).
64 Cu and 18 F Labeling. The 64 Cu labeling was performed as previously described (34) . Briefly, NODAGA-RM1 or NODAGA-AMBA (2 nmol each) was dissolved in NaOAc buffer (0.1 M, pH 5.0) and labeled with 64 Cu (74 MBq [2 mCi]) for 60 min at 37°C. The labeled peptides were then purified by analytic HPLC. The radioactive peaks containing the desired products were collected and rotary-evaporated to remove the solvent. The products were then formulated in phosphate-buffered saline (1·, pH 7.4) and passed through a 0.22-mm Millipore filter into a sterile vial for the subsequent in vitro and in vivo experiments. The labeling yield was above 90% for all of the probes.
The 18 F-AlF labeling was performed as previously described (33) . A QMA SepPak Light cartridge (Waters) fixed with 18 F (1.1 GBq [30 mCi]) was washed with 2.5 mL of metal-free water. The 18 F was then eluted from the cartridge with 400 mL of 0.4 M KHCO 3 , from which 200-mL fractions were taken. The pH of the solution was adjusted to 4 with metal-free glacial acetic acid. AlCl 3 (2 mM, 3 mL) in 0.1 M sodium acetate buffer (pH 4) and 10 mL of peptide (1 mg/mL in dimethyl sulfoxide) were then added to the reaction solution sequentially. The reaction mixtures were incubated at 100°C for 15 min. The labeled peptides were then purified by semipreparative HPLC. The fractions containing the desired products were collected and rotary-evaporated to remove the solvent. The products were reconstituted in phosphate-buffered saline and passed through a 0.22-mm Millipore filter into sterile vials for the subsequent in vitro and in vivo experiments.
Cell-Binding Assays
The cell-binding assay was performed similarly as previously reported (19, 35) . The detailed procedures are included in the supplemental file.
Mouse Serum Stability
The in vitro stability of the PET probes was evaluated by incubation with mouse serum (1 mL) at 37°C. The solutions were filtered using a NanoSep 10 K centrifuge (Pall Corp.) to isolate low-molecular-weight radiocomplexes. The samples were analyzed by the radio-HPLC, and the percentages of intact PET probe were determined by quantifying the peaks corresponding with the intact probe and degradation products.
Small-Animal PET Imaging
The animal procedures were performed according to a protocol approved by the Stanford University Institutional Animal Care and Use Committee. The establishment of the PC3 tumor mice model and the procedure for small-animal PET are shown in the supplemental file.
The PC3 xenograft-bearing mice were injected with approximately 1.85 MBq (50 mCi) of either 64 Cu-NODAGA-RM1 or 64 Cu-NODAGA-AMBA via the tail vein (n 5 4 for each group). At the indicated times after injection (0.5, 1.5, and 4 h), the mice were anesthetized with isoflurane (5% for induction and 2% for maintenance in 100% O 2 ) using a knock-down box. Five-minute static scans were then obtained. The PC3 xenograft-bearing mice were injected with 0.37 MBq (10 mCi) of either 18 F-AlF-NODAGA-RM1 or 18 F-AlF-NODAGA-AMBA probe via the tail vein (n 5 5 for each group). Blocking studies were performed via tail vein injection of the 18 F probe with cold AMBA (10 mg/kg of body weight) (n 5 5). At 0.5, 1, and 2 h after injection, the small-animal PET images were obtained.
The small-animal PET images were reconstructed using the 2-dimensional ordered-subsets expectation maximization algorithm. No background correction was performed. The regions of interest (ROIs; 5 pixels for coronal and transaxial slices) were designated over the tumor on decay-corrected whole-body coronal images. The maximum counts per pixel per minute were obtained from the ROIs and converted to counts per milliliter per minute using a calibration constant. On the basis of an assumed tissue density of 1 g/mL, the ROIs were converted to counts per gram per min. The image ROI-derived percentage of the injected radioactive doses per gram of tissue (%ID/g) values were determined by dividing counts per gram per minute by injected dose. No attenuation correction was performed.
Animal Biodistribution Studies
The PC3 xenograft-bearing nude mice (n 5 4 for each group) were injected with approximately 1.85 MBq (50 mCi) of 64 Cu-AlF-NODAGA-RM1 via the tail vein and sacrificed at 2 and 24 h after injection. The tumor and normal tissues of interest were removed and weighed, and their levels of radioactivity were measured using a g-counter. The uptake of radioactivity in the tumor and normal tissues was expressed as %ID/g. Similarly, PC3 xenograft-bearing nude mice (n 5 5 for each group) were injected with approximately 0.37 MBq (10 mCi) of 18 F-AlF-NODAGA-RM1 via the tail vein and sacrificed at 2 h after injection. The 18 F-AlF-NODAGA-RM1 blocking study was performed by coinjection of the probe with the AMBA peptide (10 mg/kg of body weight) via the tail vein.
Statistical Analysis
The quantitative data are expressed as the mean values 6 SD. The mean values were compared using a 1-way ANOVA and Student t test. P values of less than 0.05 were considered statistically significant.
RESULTS

Chemistry and Radiochemistry
The G-4-aminobenzoyl-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH 2 64 Cu-NODAGA-RM1 and 64 Cu-NODAGA-AMBA were synthesized in high yield (.85%), and their specific activities were calculated as greater than 29.6 GBq/mmol (800 mCi/mmol). The radiosynthesis of the 18 F-AlF-NODAGA-RM1 and 18 F-AlF-NODAGA-AMBA was completed within 40 min, with decay-corrected yields of 5.6% 6 1.1% and 4.9% 6 1.3%, respectively, and the radiochemical purity of the probes was more than 95%. The specific activities of the purified 18 F-AlF-NODAGA peptides were calculated as greater than 1.85 GBq/mmol (50 mCi/mmol).
Cell-Binding Affinity Assay
The receptor-binding affinity assay results for the RM1, NODAGA-RM1, AMBA, and NODAGA-AMBA probes are shown in Figure  2 . All of these peptides inhibited the GRPR binding of 125 I-[Tyr 4 ] BBN on the PC3 cells in a concentration-dependent manner. The half maximal inhibitory concentration values for RM1, NODAGA-RM1, AMBA, and NODAGA-AMBA were 0.25 6 0.04, 4.6 6 1.0, 0.17 6 0.07, and 1.9 6 0.50 nM (n 5 4), respectively. These results suggest that the incorporation of the NODAGA motif reduced the GRPR-binding affinity of the original peptides but that the resulting bioconjugates still possessed significantly high affinities, warranting further biologic evaluation.
Serum Stability of Radiolabeled NODAGA Peptides
Both 64 Cu-NODAGA-RM1 and 18 F-AlF-NODAGA-RM1 exhibited favorable stability in mouse serum. More than 90% of the probes remained intact after 1 h of incubation in mouse serum at 37°C. However, 64 Cu-NODAGA-AMBA and 18 F-AlF-NODAGA-AMBA exhibited degradation under the same conditions (supplemental data).
Small-Animal PET Imaging Studies
Representative decay-corrected coronal images of static scans at different time points after injection are shown in Figures 3-5 . The PC3 tumors were clearly visualized using all of the PET probes. The PC3 tumors were visualized using 64 Cu-NODAGA-RM1 and 64 Cu-NODAGA-AMBA, with favorable tumor-to-background contrast, even at 0.5 h (Fig. 3A) . Interestingly, 64 Cu-NODAGA-RM1 exhibited persistent accumulation within the tumor until 4 h after injection, whereas 64 Cu-NODAGA-AMBA exhibited more rapid tumor clearance and significantly reduced signal within the tumor at 4 h after injection. Further image quantification analysis confirmed the visualization results. The uptake of 64 Cu-NODAGA-RM1 within the PC3 tumors was 3.3 6 0.38, 3.0 6 0.76, and 3.5 6 1.0 %ID/g at 0.5, 1.5, and 4 h after injection, respectively. In contrast, 64 Cu-NODAGA-AMBA exhibited only 3.2 6 0.60, 2.2 6 0.33, and 1.8 6 0.10 %ID/g tumor uptake at 0.5, 1.5, and 4 h after injection, respectively (Figs. 3B and 3C) . Moreover, both PET probes exhibited significant accumulation in both the liver and the kidneys (.10 %ID/g), indicating their clearance through both the hepatobiliary and the renal systems. Quantification analysis also revealed that 64 Cu-NODAGA-RM1 exhibited significantly reduced kidney uptake at 0.5 and 1.5 h, compared with 64 Cu-NODAGA-AMBA (P , 0.05), whereas no significant differences were observed between their levels of either kidney uptake at 4 h after injection or liver uptake at all of the time points (Figs. 3B and 3C ). Increased tumor-to-normal-tissue ratios (tumor to liver, tumor to kidney, and tumor to muscle) were observed for 64 Cu-NODAGA-RM1, compared with those for 64 Cu-NODAGA-AMBA (Fig. 3D) . Overall, 64 Cu-NODAGA-RM1 exhibited superior in vivo performance, compared with the 64 Cu-NODAGA-AMBA probe.
The small-animal PET images and quantification analyses for 18 4A and 5A, top), both probes accumulated rapidly within the tumor, and favorable tumor-to-background imaging contrasts were achieved at 0.5 h after injection. Furthermore, the coinjection of the unlabeled GRPRtargeting peptide AMBA significantly reduced the uptake of both probes (P , 0.05), resulting in significantly reduced tumorto-background contrast in vivo (Figs. 4A  and 5A, bottom) . These results clearly demonstrated the excellent in vivo targeting ability and specificity of both probes. Moreover, similar to the 64 Cu-labeled peptides, 18 F-AlF-NODAGA-AMBA exhibited more rapid tumor clearance than 18 F-AlF-NODAGA-RM1 (Figs. 4A and 5A, top) . Quantification analysis indicated that the tumor uptake of 18 F-AlF-NODAGA-AMBA was 3.7 6 0.70, 2.4 6 0.24, and 1.4 6 0.13 %ID/g at 0.5, 1, and 2 h, respectively (Fig. 4B) , whereas the tumor uptake of 18 F-AlF-NODAGA-RM1 was 4.6 6 1.5, 4.0 6 0.87, and 3.9 6 0.48 %ID/g at 0.5, 1, and 2 h, respectively (Fig. 5B) . At 1 and 2 h after injection, the tumor uptake of 18 F-AlF-NODAGA-RM1 was significantly increased, compared with that of 18 F-AlF-NODAGA-AMBA (P , 0.05). The coinjection of 18 F-AlF-NODAGA-AMBA or 18 F-AlF-NODAGA-RM1 with blocking doses of AMBA also significantly reduced their tumor uptake (Figs. 4B and 5B). The tumor uptake was 0.66 6 0.19, 0.55 6 0.15, and 0.39 6 0.18 %ID/g for 18 F-AlF- 64 Cu-labeled counterparts, both 18 F-AlF-NODAGA-AMBA and 18 F-AlF-NODAGA-RM1 were excreted through both the hepatobiliary and the renal systems. Taken together, these results clearly suggest 18 F-AlF-NODAGA-RM1 to be a more promising probe than 18 F-AlF-NODAGA-AMBA.
Biodistribution Studies
Next, we performed a biodistribution study of 64 Cu-NODAGA-RM1 and 18 F-AlF-NODAGA-RM1. The results are shown in Table 1 . The tumor uptake for 64 Cu-NODAGA-RM1 at 2 and 24 h after injection were 4.30 6 0.98 and 2.62 6 0.32 %ID/g, respectively. 64 Cu-NODAGA-RM1 also showed relatively low kidney and liver uptake.
Without the presence of AMBA peptide as a blocking agent at 2 h after injection, the tumor, liver, and kidney uptake for 18 F-AlF-NODAGA-RM1 (~0.37 MBq [10 mCi]/mouse, n 5 5) was 5.2 6 0.84, 2.5 6 0.96, and 4.6 6 1.9 %ID/g, respectively. In contrast, the same organ uptake for the blocking group was 1.8 6 0.30, 1.9 6 0.19, and 7.3 6 2.1 %ID/g, which is consistent with the PET imaging results. Increased pancreatic uptake in the control tumor mice (5.1 6 1.4 %ID/g), which is in contrast with reduced pancreatic uptake in the blocking mice (0.54 6 0.13 %ID/g), was also observed. Again, the significantly reduced uptake of the probe in the GRPR-positive tissues, including the PC3 tumor and pancreas, confirmed the receptor-targeting specificity of the probes. Data are expressed as normalized accumulation of activity in %ID/g 6 SD (n 5 5). 
DISCUSSION
In this study, 2 important BBN peptides, AMBA and RM1, were labeled with 18 F and used for PET imaging of PCa for the first time. These 2 peptides were first modified with the chelator NODAGA to render the bioconjugates more easily labeled with 64 Cu and 18 FAlF to form stable radiocomplexes. After modification with NODAGA, the half maximal inhibitory concentration of each of the conjugated peptides was still within the nanomolar range (Fig. 2) . Therefore, they were further radiolabeled with 64 Cu and 18 F-AlF and tested in vivo.
The radiolabeling of NODAGA-AMBA and NODAGA-RM1 with 64 Cu is a relatively simple and straightforward process. Al-F chelation chemistry has been used for 18 F labeling, as pioneered by McBride et al., and this strategy has many advantages, such as short labeling time and water compatibility (31) . We previously synthesized 18 F-AlF-NOTA-RGD 2 as a PET probe for tumor angiogenesis imaging (33) . The favorable in vivo performance of several 18 F-AlF-labeled peptides reported thus far, together with their short routes of radiosynthesis, highlight the potential accelerated clinical translation of 18 F-labeled peptides using this novel radiofluorination strategy. Thus, we explored this straightforward, single-step and powerful labeling strategy to radiofluorinate AMBA and RM1. Interestingly, compared with the yield produced by the 18 F-AlF radiolabeling of NOTA-RGD 2 (17.9%), the yields produced by NODAGA-RM1 and NODAGA-AMBA were approximately 5% decay-corrected, which was likely caused by the different chelating moieties used (36) . But these labeling yields are still sufficient for producing enough PET probes for further in vitro and in vivo evaluation.
According to the in vitro serum stability assay and in vivo imaging results, both the 64 Cu-and the 18 F-labeled NODAGA-AMBA probes were less stable than the NODAGA-RM1 probes. Moreover, the 64 Cu-and 18 F-labeled NODAGA-RM1 probes exhibited more favorable in vivo tumor retention and imaging quality than the 64 Cu-and 18 F-labeled NODAGA-AMBA probes (Figs. 3-5) . BBN peptide antagonists and agonists exhibited different stabilities and in vivo behavior. Schroeder et al. reported that the antagonist demobesin-1 exhibits superior in vivo stability, increased tumor uptake and retention, and faster pancreatic and renal clearance than the other 4 GRPR agonists (37). Mansi et al. also compared the performance of the radioantagonist 111 In-RM1 with the radioagonist 111 In-AMBA (24) . 111 In-RM1 demonstrated relatively lower affinity for GRPR but more favorable pharmacokinetics and targeting properties, as supported by increased tumor uptake and tumor-to-normal-tissue ratios. 111 In-RM1 appeared to be superior to AMBA for in vivo SPECT imaging and for the targeted radiotherapy of GRPR-positive tumors. Consistent with these findings, our study using 64 Cu and 18 F-AlF demonstrated that antagonist RM1-based PET probes exhibit significantly increased stability and more optimal imaging performance than the agonist AMBAbased probes.
Recently, NOTA-8-Aoc-BBN(7-14)-NH 2 was labeled with 18 F using the Al-18 F method described by Dijkgraaf et al., and the results showed that the AlF method does not affect the in vivo behavior of the peptide (38) . For example, the uptake of 18 F-labeled NOTA-8-Aoc-BBN(7-14)-NH 2 in the PC3 tumors was 2.15 6 0.55 %ID/g, which is similar to the 64 Cu-labeled NOTA-8-Aoc-BBN (7) (8) (9) (10) (11) (12) (13) (14) conjugate (3.59 6 0.70 %ID/g) at 1 h after injection (18) . In our study, 18 F-AlF-NODAGA-RM1 also exhibited uptake similar to 64 Cu-NODAGA-RM1 (4.6 6 1.5 vs. 3.3 6 0.38 at 0.5 h and 4.0 6 0.87 vs. 3.0 6 0.76 at 1 h, respectively). More importantly, 18 F-AlF-NODAGA-RM1 exhibited increased tumor uptake, compared with 18 F-AlF-NOTA-8-Aoc-BBN (7-14)NH 2 (4.0 6 0.87 vs. 2.15 6 0.55), highlighting the advantages of using RM1 for PET probe development. Taken together, on the basis of their favorable in vitro serum stability and in vivo tumor imaging properties (Figs.  3 and 5) , 64 Cu-NODAGA-RM1 and 18 F-AlF-NODAGA-RM1 warrant further investigation for clinical translation. In particular, the radioantagonist 18 F-AlF-NODAGA-RM1 demonstrated wide availability, easy radiosynthesis, increased tumor uptake, and tumor-to-background contrast. Moreover, considering the different physical properties and availability of 64 Cu and 18 F, 18 F-AlF-NODAGA-RM1 holds significant promise for imaging PCa in clinical applications.
CONCLUSION
NODAGA-RM1 and NODAGA-AMBA have been successfully prepared and radiolabeled with 64 Cu and 18 F. The radiolabeling methods are simple and straightforward. In vitro assay and in vivo studies showed that 64 Cu-and 18 F-labeled NODAGA-AMBA are limited by certain undesirable properties, such as relatively low stability and rapid tumor clearance. However, both 64 Cu-NODAGA-RM1 and 18 F-AlF-NODAGA-RM1 exhibit excellent in vitro serum stability and in vivo tumor imaging properties. In particular, 18 FAlF-NODAGA-RM1 exhibited increased tumor uptake and favorable pharmacokinetics, representing a highly promising probe for the PET imaging of PCa in clinical applications.
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